Novel Therapy Yields High Remission and Response Rates in Pediatric R/R B-ALL
Bicistronic CD19/CD22 CAR T-cell therapy had improved safety, durability, and high remission rates in pediatric patients with R/R B-ALL.
Related Articles
Working on the Frontlines of a Revolution in Multiple Myeloma Care
A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly…
Growing Evidence Suggests Plant-Based Diets Reduce Cancer Risk
As evidence accumulates on the protective effects of a plant-heavy diet against cancers, experts explain how providers can incorporate those findings into routine medical visits.
Final analysis from a Phase I trial of asciminib in T315I-mutated CML-CP
Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, briefly comments on the final analysis of a Phase…
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Tarlatamab Earns UK Approval for Previously Treated ES-SCLC
Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis
Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.
Anito-Cel Demonstrates Safety and Early Efficacy in R/R Multiple Myeloma
Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.